Proteomics International Laboratories (PIQ) Q4 2026 TU earnings summary

Executive summary

• Completed a corporate restructure, reducing headcount by 25% and appointing a new CFO, to shift focus from research to commercial diagnostics.

• Entered a national distribution agreement with Healius Limited for the Promarker® portfolio in Australia, with phased rollout planned for FY27.

• Advanced PromarkerD reimbursement readiness and published a US health economics manuscript.

• Secured a US patent for PromarkerEndo, strengthening IP in endometriosis diagnostics.

• Renewed Australian laboratory accreditations and continued assay validation and protocol improvements.

Financial highlights

• Cash outflows from operations were $2.08 million for the quarter ended 30 June 2026, including $0.46 million in one-off redundancy and entitlement payments.

• Cash and cash equivalents stood at $3.5 million at quarter end, down from $5.69 million at 31 March 2026.

• Receipts from customers totaled $128,000 for the quarter.

• Outflows included $1.09 million for staff, admin, and corporate costs, $0.87 million for R&D, and $0.29 million for product manufacturing, operating, advertising, and marketing.

• Payments to related parties totaled $208,000, covering director fees and executive remuneration.

Outlook and guidance

• The Healius distribution agreement is expected to drive commercialisation, but revenue impact is not yet reliably estimable.

• Restructure is projected to deliver annualised cost savings of over $1 million.

• Company expects to receive an R&D Tax Incentive refund in H1 FY27.

• Ongoing evaluation of funding needs and capital management alternatives.